Cangene lands hemophilia asset slapped with FDA complete response letter
This article was originally published in Scrip
Executive Summary
Cangene must be feeling hard done by this week. Ipsen of France and its US partner Inspiration Biopharmaceuticals, which filed for Chapter 11 bankruptcy protection last October, revealed that they received a complete response letter (CRL) for the hemophilia B product, IB1001 (recombinant factor IX). They broke the news simultaneously with the closing of the sale of the asset to Cangene. The deal was first announced on 6 February but it is unclear exactly when the CRL was received. No mention was made of the CRL prior to today.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.